Health · Medical Research · 49 mins ago

AR1001 slows decline in some people with early Alzheimer’s in trial

AR1001 slows decline in some people with early Alzheimer’s in trial

A phase III trial tested the daily pill AR1001 in 1,535 people with Alzheimer’s at 230 sites in 13 countries, including the United Kingdom.

The drug, also called mirodenafil, is made by South Korean firm AriBio and belongs to the same drug class as sildenafil, used in Viagra.

Participants taking AR1001 alone showed 31 per cent less decline in memory, thinking and everyday activities than those given a placebo over one year, equivalent to a delay of about 3.5 months.

Results were mixed for people taking other dementia medicines: the reported benefit was 7 per cent and was not statistically significant.

Most side effects were mild or moderate; diarrhoea, falls and dizziness were among the most common.

The findings suggest the tablet may slow decline, but further investigation is needed, particularly for people taking other dementia drugs.

3 sources

Related

What people are saying

Dr Richard OakleyAssociate Director for Research and Innovation at Alzheimer's Society
These topline results are an encouraging sign that we could have a new treatment for early Alzheimer's disease that tackles its causes, not just its symptoms.
via Daily Mail
However, results were not apparent in people taking other drugs for Alzheimer's symptoms, so this needs further investigation.
via Daily Mail